Nilsine Partners LLC Buys Shares of 33,519 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Nilsine Partners LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 33,519 shares of the biopharmaceutical company’s stock, valued at approximately $700,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Pacer Advisors Inc. raised its stake in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after purchasing an additional 151,495 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Catalyst Pharmaceuticals by 4.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock valued at $23,215,000 after acquiring an additional 50,804 shares during the last quarter. Point72 Asset Management L.P. grew its position in Catalyst Pharmaceuticals by 47.9% in the second quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company’s stock worth $9,577,000 after acquiring an additional 200,370 shares during the period. AQR Capital Management LLC increased its stake in Catalyst Pharmaceuticals by 87.1% during the second quarter. AQR Capital Management LLC now owns 488,386 shares of the biopharmaceutical company’s stock worth $7,565,000 after acquiring an additional 227,321 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock valued at $8,116,000 after purchasing an additional 33,888 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ CPRX opened at $22.84 on Wednesday. The stock has a market cap of $2.72 billion, a P/E ratio of 19.36, a PEG ratio of 2.28 and a beta of 0.79. The business’s fifty day simple moving average is $21.86 and its 200-day simple moving average is $20.61. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.12 and a 12-month high of $24.27.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares in the company, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 in the last quarter. Corporate insiders own 11.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. StockNews.com downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Bank of America reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Stephens started coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, HC Wainwright raised their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.86.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.